{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Summarized with contingency tables or scatterplots, and with quantitative measures of agreement.","groups":[{"description":"Patients receive PXD101 IV at 1000 mg/m2 over 30 minutes on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\nbelinostat: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Belinostat)"}],"populationDescription":"IHC data were not collected.","reportingStatus":"POSTED","timeFrame":"At baseline and at 4 hours after last dose of PXD101 on day 5","title":"Histone Acetylation by IHC and Western Blotting","type":"SECONDARY"}